Noninferiority Effects on Glycemic Control and β-Cell Function Improvement in Newly Diagnosed Type 2 Diabetes Patients: Basal Insulin Monotherapy Versus Continuous Subcutaneous Insulin Infusion Treatment
| العنوان: | Noninferiority Effects on Glycemic Control and β-Cell Function Improvement in Newly Diagnosed Type 2 Diabetes Patients: Basal Insulin Monotherapy Versus Continuous Subcutaneous Insulin Infusion Treatment |
|---|---|
| المؤلفون: | Hongrong Deng, Xiaofeng Li, Longyi Zeng, Hongyun Lu, Panwei Mu, Man-man Wang |
| المصدر: | Diabetes Technology & Therapeutics. 14:35-42 |
| بيانات النشر: | Mary Ann Liebert Inc, 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Blood Glucose, Male, China, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Type 2 diabetes, Infusions, Subcutaneous, Gastroenterology, Insulin Infusion Systems, Endocrinology, Insulin Detemir, Diabetes mellitus, Internal medicine, medicine, Humans, Hypoglycemic Agents, Insulin detemir, Glycemic, Glycated Hemoglobin, Glucose tolerance test, medicine.diagnostic_test, business.industry, Insulin, Type 2 Diabetes Mellitus, Original Articles, Glucose Tolerance Test, Middle Aged, Postprandial Period, medicine.disease, Insulin, Long-Acting, Medical Laboratory Technology, Treatment Outcome, Postprandial, Diabetes Mellitus, Type 2, Female, business, medicine.drug |
| الوصف: | In newly diagnosed type 2 diabetes mellitus (T2DM) patients, short-term insulin therapy might improve β-cell function and glycemic control. This study aimed to compare the effects of basal insulin monotherapy with continuous subcutaneous insulin infusion (CSII) treatment.Fifty-nine cases of newly diagnosed T2DM patients with fasting plasma glucose of 9.0-16.7 mmol/L were recruited into this study. They were hospitalized and randomly assigned to a basal insulin monotherapy group (n=27) or a CSII group (n=32). Insulin dosage was titrated according to fasting capillary blood glucose levels, and treatment was stopped after 2 weeks. Intravenous glucose tolerance tests were performed, and blood glucose, insulin, C-peptide, and lipid profiles were measured before therapy and 2 days after therapy withdrawal.Both treatments reduced fasting and postprandial blood glucose levels (after treatment vs. baseline, both P0.05). Fasting glycemic control target was achieved in 52 cases (88.14%) with 2 weeks of insulin treatment, and there were no significant differences between the glargine and CSII groups (P=0.059). The time to achieve fasting glycemic target in the CSII group was shorter than that in the glargine group (P0.01). Plasma lipid profiles such as triglycerides and total cholesterol also decreased significantly after the intervention. Overall β-cell function improved significantly after insulin intervention (P0.01). Variation did not differ between two groups, nor did the effects on insulin and C-peptide secretion (P0.05).The effect of basal insulin monotherapy was similar to that of CSII, and thus basal insulin monotherapy might be a reasonable alternative to CSII for initial insulin therapy in newly diagnosed T2DM patients. |
| تدمد: | 1557-8593 1520-9156 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::780d1504b48c2a98474a0294ec368797Test https://doi.org/10.1089/dia.2011.0123Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....780d1504b48c2a98474a0294ec368797 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15578593 15209156 |
|---|